Intercept Pharmaceuticals Reports Q1 2023 Net Loss of $32.1 Million

Intercept Pharmaceuticals, Inc.(ICPT) has released its financial statement s for the first quarter of 2023, reporting a net loss of $32.1 million. The company's revenue for the same period reached $67.9 million. Let's delve deeper into the details of the financial performance during Q1 2023.

Net Income/Loss

Intercept Pharmaceuticals experienced a net loss of $32.1 million for the three months ended March 31, 2023. This loss can be attributed to various factors, including operating expenses and other expenses. The net loss per common and potential common share (basic and diluted) for the quarter was $0.77.

The loss from continuing operations amounted to $31.9 million, while there was an additional loss of $0.3 million from discontinued operations.